Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.
From the official U.S. FDA label for erythromycin, the active ingredient registered with NAFDAC.
Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris.
The following local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with topical use of erythromycin. Generalized urticarial reactions possibly related to the use of erythromycin, which required systemic steroid therapy have been reported.
Erythromycin Topical Solution USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. …
Pregnancy: Teratogenic Effects: Pregnancy Category B - There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. …
Store in a dry place at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature].
Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.
Eryfast-125 Oral Suspension** (duplicate) contains Erythromycin (125 mg/5 mL), as suspension, according to its NAFDAC registration record.
Yes. Eryfast-125 Oral Suspension** (duplicate) is listed on the NAFDAC register under registration number A4-8607, and its registration is active as of 6 November 2026.
No WHO falsified or substandard medical product alert currently matches Eryfast-125 Oral Suspension** (duplicate) in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number A4-8607, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris. (Summarised from the official U.S. FDA label for erythromycin. Always follow your doctor or pharmacist.)
Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.